Intuitive Surgical Q1 results likely to be strong, says Cantor After Intuitive Surgical announced that its board has authorized an additional $1B share repurchase program and Massachusetts regulators called for increased scrutiny of robotic surgery, Cantor believes that Intuitive Surgical's risk/reward is still attractive. The firm reiterates a $575 price target and Buy rating.
Intuitive Surgical initiated with a Neutral at Piper Jaffray Piper Jaffray analyst Matt O'Brien started shares of Intuitive Surgical with a Neutral rating and $505 price target. O'Brien calls the stock "simply too expensive" relative to expected sales and earnings, but admits Intuitive's robotic surgical technology will likely dominate the market in the coming years. Further, the analyst thinks the company's da Vinci Prostatectomy and da Vinci Hysterectomy procedures could contract amid new diagnostic tests and insurance pushback. The stock closed yesterday up $2.05 to $496.37.